Bellevue Group’s Acceleron Pharma XLRN Stock Holding History

Bellevue Group’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-21,700	Closed	-$1.95M	–	230
2020 Q1	$1.95M	Sell	21,700 -2,500	-10%	-$194K	0.04%	130
2019 Q4	$1.28M	Sell	24,200 -1,600	-6%	-$73K	0.02%	146
2019 Q3	$1.02M	Buy	+25,800	New	+$1.12M	0.02%	144
2019 Q1	–	Sell	-14,300	Closed	-$623K	–	153
2018 Q4	$623K	Sell	14,300 -1,900	-12%	-$94.9K	0.04%	128
2018 Q3	$927K	Buy	+16,200	New	+$796K	0.06%	127

Other funds holding XLRN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Bellevue Group's XLRN Position: Q2 2020 in Review

Bellevue Group sold out of Acceleron Pharma (XLRN) in Q2 2020, closing a stake of 21,700 shares — an estimated $1.95M sold.

Bellevue Group first reported a position in XLRN in Q3 2018 and held it in 5 quarters. The position peaked at $1.95M in Q1 2020. 242 funds tracked by Wall St. Rank hold XLRN as of Q2 2020.

Bellevue Group reported no remaining Acceleron Pharma position as of Q2 2020 after selling out during the quarter.
Bellevue Group sold 21,700 Acceleron Pharma shares in Q2 2020, an estimated $1.95M.
Bellevue Group first reported a position in Acceleron Pharma in Q3 2018 and held it in 5 quarters.
Bellevue Group's Acceleron Pharma position peaked at $1.95M in Q1 2020.
242 funds tracked by Wall St. Rank held Acceleron Pharma as of Q2 2020.

Based on Bellevue Group's 13F filing for Q2 2020, filed 13 Aug 2020.